Recipharm Signs Partnership Agreement with Follicum
News Jun 04, 2015
Recipharm has announced that it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005.
Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.
“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” says Jan Alenfall, CEO of Follicum.
“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” says Maria Lundberg, General Manager of Recipharm in Solna.
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE